search
Back to results

Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System-Canada

Primary Purpose

Chronic Venous Insufficiency

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
BlueLeaf Procedure
Sponsored by
Intervene, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Venous Insufficiency

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 1. 18 years of age or older;
  • 2. Symptomatic CVI subjects, Clinical Etiological Anatomical Pathophysiological (CEAP) classification 4 to 6;
  • 3. Failed at least 6 months of conservative therapy at some point during the course of their CVI management (symptoms not adequately resolved or patient non-compliant/unable to tolerate);
  • 4. Willing and able to sign the approved informed consent form (ICF);
  • 5. Willing to comply with follow-up evaluations and protocols;
  • 6. Deep system venous reflux characterized by >1 second reflux time in two contiguous vein segments (vein segments defined as: proximal femoral, distal femoral, and popliteal), as assessed by DUS with patient in the standing position;
  • 7. Presence of at least two potential target sites within the target vessel, which is defined as a segment within the femoral or popliteal vein that is:

    • not less than 7mm in luminal diameter, and
    • not more than 11mm in luminal diameter, and
    • at least 3cm long (two target sites in a row must be spaced at least 1cm apart), and
    • absent severe obstructive features such as thrombus, synechiae, natural valves, major tributaries (valves can be formed opposite tributaries) or severe heterogeneous fibrotic changes of the vessel wall which, in the Investigator's opinion, would preclude formation of a valve, as preliminary assessed by DUS, and then by IVUS, while the vein is under physiologically appropriate hemodynamic pressure, with IVUS being the definitive modality.
  • 8. In the Investigator's opinion, the subject is a good candidate for treatment with the BlueLeaf System based on their symptoms, quality of life, anatomy, and the likelihood of benefit from continued conservative therapy.

Exclusion Criteria:

  • 1. Untreated significant superficial venous incompetence within 30 days of screening which, in the opinion of the Investigator, may be the primary source of existing symptoms;
  • 2. A competent vein valve in any vein segment through which the device is likely to be inserted, as assessed by DUS (<1 second reflux time) or with contrast venography (Investigator's opinion);Deep venous intervention (includes stenting) in the target limb or outflow vessels within 90 days of consent;
  • 3. Deep venous intervention (includes stenting) in the target limb or outflow vessels within 90 days of consent
  • 4. Significant peripheral arterial disease with an ankle-brachial index of <0.70 or with incompressible vessels;
  • 5. Contraindications to all protocol specified anticoagulation options;
  • 6. Known and uncontrolled hypercoagulopathy (i.e. hypercoagulopathy that cannot be adequately managed/controlled with medication);
  • 7. Acute deep venous thrombosis (DVT) within 6 months of consent;
  • 8. Comorbidity risks or other concerns (e.g. recent cancer) which, in the opinion of the Investigator, limit longevity or likelihood of complying with the protocol and its prescribed follow up or would preclude the patient from open surgery in the event of a complication requiring surgical intervention (e.g. severe vein laceration);
  • 9. General contraindications to local, regional or general anesthesia required for the index procedure;
  • 10. NYHA Class III or IV heart failure;
  • 11. Active systemic infection;
  • 12. Women on long-term oral contraceptives;
  • 13. Subject is enrolled in another clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results;
  • 14. Invasive surgical procedure within the last 90 days that in the Investigator's opinion would interfere with the study procedure or results;
  • 15. History of stroke within the last 6 months;
  • 16. Flow-limiting venous outflow obstruction central to the intended target sites, defined by a common femoral vein duplex exam found to have a continuous waveform without respiratory variation or a 50% or greater reduction in luminal cross-sectional area on IVUS;
  • 17. Inadequate flow into or through the target vessel (Investigator's opinion);
  • 18. Anatomy that does not support proper device access of the treatment vein through the ipsilateral common femoral or femoral vein;
  • 19. Luminal diameter <7 mm between the vein access site and the intended treatment site, as assessed by IVUS, while the vein is under physiologically appropriate hemodynamic pressure;
  • 20. A competent vein valve in any vein segment through which the device is likely to be inserted (common femoral or femoral vein)
  • 21. Chronic renal insufficiency with creatinine level of ≥2mg/dL;
  • 22. Hemoglobin level <9.0 mg/dL;
  • 23. Platelet count <50,000 or >1,000,000 per mm3;
  • 24. Total white blood cell count <3,000/mm3;
  • 25. Pregnant or lactating female; positive pregnancy test, women of childbearing potential must be tested;
  • 26. Non-ambulatory patients;
  • 27. Patients with a history of right heart failure occurring as a consequence of, for example, biventricular failure, intrinsic pulmonary disease, chronic thromboembolic pulmonary hypertension, and other etiologies that result in elevated right-sided pressures.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Treatment

    Arm Description

    The goal of the BlueLeaf System is to percutaneously form one or more functional, autogenous deep venous valves and restore venous competence.

    Outcomes

    Primary Outcome Measures

    Change in Venous Clinical Severity Score (VCSS)
    A decrease in score from baseline

    Secondary Outcome Measures

    Full Information

    First Posted
    September 8, 2021
    Last Updated
    October 4, 2023
    Sponsor
    Intervene, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05047302
    Brief Title
    Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System-Canada
    Official Title
    Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System (INFINITE-Canada)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2023
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Project suspended by sponsor
    Study Start Date
    October 1, 2022 (Anticipated)
    Primary Completion Date
    November 1, 2025 (Anticipated)
    Study Completion Date
    November 1, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Intervene, Inc.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Prospective, non-randomized, multicenter pre-market feasibility study to evaluate subjects treated with the BlueLeaf System for the treatment of symptomatic CVI of the lower extremity.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Venous Insufficiency

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Treatment
    Arm Type
    Experimental
    Arm Description
    The goal of the BlueLeaf System is to percutaneously form one or more functional, autogenous deep venous valves and restore venous competence.
    Intervention Type
    Device
    Intervention Name(s)
    BlueLeaf Procedure
    Intervention Description
    The device is intended to form autogenous tissue leaflets from vein walls without the use of a permanent vascular implant.
    Primary Outcome Measure Information:
    Title
    Change in Venous Clinical Severity Score (VCSS)
    Description
    A decrease in score from baseline
    Time Frame
    1 year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 1. 18 years of age or older; 2. Symptomatic CVI subjects, Clinical Etiological Anatomical Pathophysiological (CEAP) classification 4 to 6; 3. Failed at least 6 months of conservative therapy at some point during the course of their CVI management (symptoms not adequately resolved or patient non-compliant/unable to tolerate); 4. Willing and able to sign the approved informed consent form (ICF); 5. Willing to comply with follow-up evaluations and protocols; 6. Deep system venous reflux characterized by >1 second reflux time in two contiguous vein segments (vein segments defined as: proximal femoral, distal femoral, and popliteal), as assessed by DUS with patient in the standing position; 7. Presence of at least two potential target sites within the target vessel, which is defined as a segment within the femoral or popliteal vein that is: not less than 7mm in luminal diameter, and not more than 11mm in luminal diameter, and at least 3cm long (two target sites in a row must be spaced at least 1cm apart), and absent severe obstructive features such as thrombus, synechiae, natural valves, major tributaries (valves can be formed opposite tributaries) or severe heterogeneous fibrotic changes of the vessel wall which, in the Investigator's opinion, would preclude formation of a valve, as preliminary assessed by DUS, and then by IVUS, while the vein is under physiologically appropriate hemodynamic pressure, with IVUS being the definitive modality. 8. In the Investigator's opinion, the subject is a good candidate for treatment with the BlueLeaf System based on their symptoms, quality of life, anatomy, and the likelihood of benefit from continued conservative therapy. Exclusion Criteria: 1. Untreated significant superficial venous incompetence within 30 days of screening which, in the opinion of the Investigator, may be the primary source of existing symptoms; 2. A competent vein valve in any vein segment through which the device is likely to be inserted, as assessed by DUS (<1 second reflux time) or with contrast venography (Investigator's opinion);Deep venous intervention (includes stenting) in the target limb or outflow vessels within 90 days of consent; 3. Deep venous intervention (includes stenting) in the target limb or outflow vessels within 90 days of consent 4. Significant peripheral arterial disease with an ankle-brachial index of <0.70 or with incompressible vessels; 5. Contraindications to all protocol specified anticoagulation options; 6. Known and uncontrolled hypercoagulopathy (i.e. hypercoagulopathy that cannot be adequately managed/controlled with medication); 7. Acute deep venous thrombosis (DVT) within 6 months of consent; 8. Comorbidity risks or other concerns (e.g. recent cancer) which, in the opinion of the Investigator, limit longevity or likelihood of complying with the protocol and its prescribed follow up or would preclude the patient from open surgery in the event of a complication requiring surgical intervention (e.g. severe vein laceration); 9. General contraindications to local, regional or general anesthesia required for the index procedure; 10. NYHA Class III or IV heart failure; 11. Active systemic infection; 12. Women on long-term oral contraceptives; 13. Subject is enrolled in another clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results; 14. Invasive surgical procedure within the last 90 days that in the Investigator's opinion would interfere with the study procedure or results; 15. History of stroke within the last 6 months; 16. Flow-limiting venous outflow obstruction central to the intended target sites, defined by a common femoral vein duplex exam found to have a continuous waveform without respiratory variation or a 50% or greater reduction in luminal cross-sectional area on IVUS; 17. Inadequate flow into or through the target vessel (Investigator's opinion); 18. Anatomy that does not support proper device access of the treatment vein through the ipsilateral common femoral or femoral vein; 19. Luminal diameter <7 mm between the vein access site and the intended treatment site, as assessed by IVUS, while the vein is under physiologically appropriate hemodynamic pressure; 20. A competent vein valve in any vein segment through which the device is likely to be inserted (common femoral or femoral vein) 21. Chronic renal insufficiency with creatinine level of ≥2mg/dL; 22. Hemoglobin level <9.0 mg/dL; 23. Platelet count <50,000 or >1,000,000 per mm3; 24. Total white blood cell count <3,000/mm3; 25. Pregnant or lactating female; positive pregnancy test, women of childbearing potential must be tested; 26. Non-ambulatory patients; 27. Patients with a history of right heart failure occurring as a consequence of, for example, biventricular failure, intrinsic pulmonary disease, chronic thromboembolic pulmonary hypertension, and other etiologies that result in elevated right-sided pressures.

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System-Canada

    We'll reach out to this number within 24 hrs